| Identification | Back Directory | [Name]
ABT 894 | [CAS]
799279-80-4 | [Synonyms]
ABT 894
A 422894.0
Sofiniclin
Sofinicline
ABT-894; ABT 894; ABT894
3,6-Diazabicyclo[3.2.0]heptane, 3-(5,6-dichloro-3-pyridinyl)-, (1S,5S)- | [Molecular Formula]
C10H11Cl2N3 | [MDL Number]
MFCD19443714 | [MOL File]
799279-80-4.mol | [Molecular Weight]
244.12 |
| Chemical Properties | Back Directory | [Boiling point ]
417.4±45.0 °C(Predicted) | [density ]
1.406±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
10.31±0.20(Predicted) | [color ]
Off-white to brown |
| Hazard Information | Back Directory | [Uses]
Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD)[1][2]. | [Biological Activity]
Sofiniclin (ABT 894) is an agonist of nAChR as a potential non-stimulatory study in attention deficit disorder. | [in vitro]
ABT 894 is more potent than ABT-089 at both receptor subtypes, with K i values of 1.9 nM for 125 I-α-conotoxinMII binding and of 1.3 nM for 125 I-epibatidine binding. | [in vivo]
ABT 894 (0.001 to 0.10 mg/kg, po) produces significant reductions in LIDs compared to vehicle monkey. It does not decrease LIDs in monkeys with severe nigrostriatal damage. < p> | [storage]
Store at -20°C | [References]
[1] Zhang D, et al. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov Disord. 2014 Apr;29(4):508-17. DOI:10.1002/mds.25817
[2] Zhang D, ET AL. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage. Mov Disord. 2015 Dec;30(14):1901-11. DOI:10.1002/mds.26453 |
|
| Company Name: |
InvivoChem
|
| Telephone: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|